Cohere Health

Bottom line

Cohere Health targets the prior authorization bottleneck with a payer-side AI platform claiming 90 percent automation of PA requests. The company positions itself as a unifying layer between health plans and provider networks, automating clinical documentation review and payment integrity checks. For integrated delivery networks (IDNs) and large medical groups already aligned with value-based care contracts, Cohere offers a potential path to reduce administrative burden on both sides of the transaction.

The platform is sold exclusively through enterprise agreements, which means pricing remains opaque and negotiated per contract. Implementation requires payer and provider coordination, EHR integration work, and alignment on clinical guidelines. Organizations considering Cohere should anticipate a six-month to twelve-month deployment cycle and budget for both software fees and change management overhead.

Cohere Health is best suited for large health systems or payer organizations seeking to reduce prior authorization turnaround time while maintaining clinical appropriateness guardrails. Solo practices and small groups will find the enterprise model inaccessible. The absence of published validation studies and limited grassroots clinician feedback means prospective buyers are relying primarily on vendor claims and reference calls when evaluating efficacy.

Why we picked it

Cohere Health earned the top spot in the prior authorization automation category because it addresses the full payer-provider workflow, not just the provider submission side. Most PA automation tools help clinicians assemble and submit requests faster, but they do not reduce the time payers take to review and approve. Cohere embeds on the payer side, applying natural language processing and rules engines to clinical documentation so that straightforward cases auto-approve without manual review. This dual-sided approach compresses total turnaround time, which matters more to patient care than submission speed alone.

The platform's focus on value-based care alignment distinguishes it from traditional revenue cycle management vendors adding AI features. Cohere's workflows emphasize clinical appropriateness and payment integrity rather than maximizing claim approval rates. For health systems operating under shared savings or capitated contracts, this payer-aligned posture reduces friction when negotiating PA policies and supports long-term partnership dynamics. The vendor's messaging reflects a care-management philosophy rather than a billing-optimization one, which resonates with CMIOs and medical directors navigating the shift from fee-for-service to risk-based models.

The claimed 90 percent automation rate, if validated in real-world deployments, represents a material reduction in administrative labor. Prior authorization consumes an estimated 14.6 hours per physician per week according to American Medical Association surveys, with much of that time spent on documentation assembly, faxing, phone appeals, and status tracking. If Cohere can auto-resolve nine out of ten requests within hours rather than days, the time savings accrue to both provider staff and payer medical directors. The value proposition depends on that automation claim holding across specialties, payer types, and procedure categories.

Cohere's enterprise-only distribution model means the vendor is accountable to a smaller number of sophisticated buyers who can demand contractual performance guarantees and data transparency. This creates stronger incentives for the platform to deliver measurable outcomes than a self-service SaaS model where churn is diffused across hundreds of small accounts. For large organizations willing to negotiate, the enterprise model offers leverage to secure service-level agreements on turnaround time, error rates, and audit access.

What it does well

Cohere Health automates the clinical documentation review step that historically required payer medical directors to manually assess each prior authorization request against coverage policies. The platform ingests clinical notes, lab results, imaging reports, and procedure codes from the EHR, then applies natural language processing to extract the clinical rationale and match it against payer-specific medical necessity criteria. When the documentation supports approval under clear-cut guidelines, the system auto-approves without human intervention. This reduces payer review queues and shortens provider wait times for routine requests.

The platform's payment integrity layer catches coding discrepancies and potential upcoding before claims are paid, which aligns payer financial incentives with provider workflow efficiency. By surfacing billing anomalies at the PA stage rather than post-claim adjudication, Cohere reduces the volume of retrospective audits and clawbacks that erode trust between payers and providers. For health systems operating under bundled payment or shared savings models, catching coding errors upstream prevents both payment denials and downstream reconciliation disputes.

Cohere provides a unified portal for providers to track PA status in real time, replacing the patchwork of payer-specific portals, fax loops, and phone queues that fragment the current experience. Clinical staff can see which requests are auto-approved, which are in manual review, and which require additional documentation, all within a single interface. This transparency reduces redundant status calls to payer call centers and allows care coordinators to proactively address documentation gaps before denials occur.

The vendor has built integrations with major EHR platforms including Epic, Cerner Oracle Health, and Athenahealth, allowing the platform to pull clinical data directly from the chart rather than requiring manual re-entry. This reduces transcription errors and accelerates submission time. The depth of integration varies by EHR and contract scope, but the ability to pre-populate PA forms with structured EHR data eliminates a significant source of administrative friction for providers.

Where it falls short

Cohere Health's enterprise-only business model makes the platform inaccessible to solo practitioners, small group practices, and safety-net clinics that lack the bargaining power and IT resources required for large-scale vendor negotiations. There is no self-service tier, no transparent pricing, and no pathway for a ten-physician family medicine practice to pilot the platform. This concentrates the benefits of PA automation among large health systems and payer organizations, leaving the fragmented majority of US clinicians to continue managing prior authorization manually or through legacy clearinghouse tools.

The 90 percent automation claim lacks independent validation in peer-reviewed literature, and the vendor has not published granular breakdowns by specialty, payer type, or procedure category. Automation rates likely vary widely depending on the complexity of the request. Straightforward medication approvals for chronic disease management may auto-approve at high rates, while specialized oncology regimens, experimental procedures, and off-label uses probably still require manual medical director review. Prospective buyers should demand contract language specifying the automation rate for their specific case mix and the methodology used to calculate it.

The platform's payer-side positioning introduces a structural tension for providers who view prior authorization as a barrier imposed by health plans rather than a collaborative care-management tool. Some clinician communities perceive payer-embedded automation as a way to enforce stricter denials at scale rather than reduce administrative burden. If Cohere's rules engines are tuned too conservatively, the platform could increase denial rates while automating the rejection process, which would worsen rather than improve the provider experience. The vendor's value-based care framing does not eliminate this fundamental misalignment of incentives between fee-for-service providers and cost-controlling payers.

Cohere's roadmap and feature development priorities are shaped by payer clients rather than practicing clinicians, which means the platform may prioritize payment integrity and fraud detection over workflow usability for front-line staff. Providers implementing Cohere through their contracted payers have limited influence over the platform's feature set, user interface design, and policy logic. This asymmetry could lead to frustration if the tool surfaces new documentation requirements or approval hurdles that feel like administrative bloat rather than streamlining.

Deployment realities

Implementing Cohere Health requires coordination between the payer organization, the provider network, and both parties' IT and compliance teams. The deployment timeline typically spans six to twelve months, starting with contract negotiation and technical scoping, followed by EHR integration setup, payer policy configuration, staff training, and phased rollout across specialties or service lines. Organizations should budget for project management resources, legal review of data-sharing agreements, and clinical leadership time to map existing PA workflows to the new platform.

EHR integration depth varies depending on the health system's technical architecture and the specific data elements required for PA automation. Epic-based organizations may leverage existing FHIR APIs or proprietary integration tools, but custom development work is often required to expose the clinical documentation fields Cohere needs. Smaller practices on cloud-based EHRs like Athenahealth or eClinicalWorks may face longer integration timelines if their vendor roadmap does not prioritize Cohere connectivity. IT teams should expect to dedicate developer time to integration testing, data validation, and ongoing API maintenance.

Change management is the largest non-technical deployment challenge. Front-line clinicians and administrative staff need training on when to use the Cohere portal versus existing payer portals, how to interpret auto-approval versus manual review statuses, and what documentation standards the AI expects. If the training is inadequate, staff will revert to familiar fax-and-phone workflows, undermining the automation benefits. Medical directors and care managers also require education on how to handle edge cases that the AI escalates for human review, ensuring clinical judgment remains the final arbiter for complex or high-risk requests.

Pricing realities

Cohere Health does not publish list pricing, and the enterprise model means each contract is individually negotiated based on the size of the provider network, the volume of prior authorization requests, and the scope of payer-provider integration. Typical pricing structures in the PA automation space include per-transaction fees, per-member-per-month charges, or annual platform licenses with volume tiers. Prospective buyers should expect baseline software costs in the mid-six-figure to low-seven-figure range for a regional health system or mid-sized payer, plus separate implementation and integration fees.

Hidden costs include EHR integration development, staff training, ongoing API maintenance, and payer policy updates as clinical guidelines evolve. Organizations that underestimate the change management effort or assume existing IT staff can absorb integration work without backfilling other responsibilities often see deployment timelines stretch and total cost of ownership rise. Contract terms typically lock buyers into multi-year agreements with auto-renewal clauses, making it difficult to exit if the platform underperforms or if internal priorities shift. Buyers should negotiate performance-based pricing or service-level agreement credits tied to measurable automation rates and turnaround time improvements.

Return on investment calculations depend on the baseline administrative burden and the degree to which automation reduces full-time-equivalent staff hours or accelerates revenue cycle timelines. If a health system currently employs ten full-time PA coordinators and Cohere reduces that to three, the labor savings can justify the platform cost within two years. However, if the automation primarily shifts work from manual faxing to digital form completion without eliminating roles, the ROI case weakens. Organizations should model scenarios that account for partial automation, ongoing manual review requirements, and the potential for payers to impose new documentation standards that offset efficiency gains.

Compliance + integration depth

Cohere Health must meet HIPAA security and privacy standards as a business associate handling protected health information on behalf of payer and provider clients. The vendor's website and marketing materials do not prominently disclose SOC 2 Type II audit status, HITRUST certification, or FDA clearance, which are common trust markers in the healthcare IT vendor landscape. Prospective buyers should request attestation reports, penetration test results, and incident response documentation during the procurement process to validate the platform's security posture. The absence of publicly available compliance certifications is a yellow flag, though not disqualifying for enterprise buyers with robust vendor risk assessment programs.

Integration depth with EHR platforms varies by vendor and contract scope. Cohere advertises connectivity with Epic, Cerner Oracle Health, and Athenahealth, but the level of integration ranges from read-only data pulls to bi-directional workflow automation. Epic-based organizations can potentially leverage App Orchard partnerships or proprietary APIs to embed Cohere workflows directly within the EHR user interface, reducing context switching for clinicians. Smaller EHR vendors or legacy on-premises systems may require custom HL7 interfaces or manual data exports, which increase implementation complexity and limit real-time automation capabilities.

The platform does not carry specialty-society endorsements from the American College of Physicians, the American Academy of Family Physicians, or other major clinical organizations, which limits its credibility signal to front-line practitioners. Payer-facing tools often prioritize administrative efficiency over clinician usability, and the lack of grassroots advocacy from physician groups suggests Cohere has not yet built trust within the broader medical community. Organizations should assess whether the platform's workflows align with specialty-specific PA protocols and whether vendor-provided training materials address the clinical context relevant to their patient populations.

Vendor stability + roadmap

Cohere Health has raised institutional venture capital funding, though the company does not publicly disclose funding rounds, valuation, or investor names on its website. The lack of transparency around capitalization and burn rate makes it difficult for prospective buyers to assess long-term vendor viability. Organizations committing to multi-year contracts should request financial stability representations, customer reference lists, and contractual protections in the event of acquisition or wind-down. The absence of public financing disclosures is common among enterprise-focused healthcare IT vendors but represents a due diligence gap for risk-averse buyers.

The vendor's leadership and customer base are not prominently featured in public-facing materials, which limits the ability to independently verify deployment scale and customer satisfaction. Organizations evaluating Cohere should request access to existing customers for reference calls, preferably within similar care settings and with comparable PA volumes. Vendor-curated references are inherently biased, but the willingness to connect prospective buyers with multiple long-term clients signals confidence in the platform's real-world performance.

Cohere's publicly stated roadmap emphasizes value-based care alignment and payment integrity, suggesting future development will prioritize payer use cases over provider workflow optimization. This direction aligns with the company's payer-side positioning but may limit feature investment in areas that matter most to clinicians, such as mobile-friendly PA submission, real-time denial reason transparency, or peer-to-peer appeal automation. Providers should clarify whether their contracted payers have influence over Cohere's product roadmap and whether the vendor commits to regular feature releases that address provider-side pain points.

How it compares

Waystar, formerly Zirmed, offers a competing prior authorization automation platform embedded within a broader revenue cycle management suite. Waystar's strength is its breadth of payer connectivity and its focus on provider-side workflow optimization, making it a better fit for health systems that want end-to-end RCM rather than a standalone PA tool. Waystar's pricing is also enterprise-negotiated, but the vendor has a larger installed base and more published case studies. Cohere wins when the buyer prioritizes payer-provider alignment and value-based care workflows over pure RCM throughput.

Change Healthcare, a UnitedHealth Group subsidiary, provides prior authorization and eligibility verification through its Intelligent Healthcare Network. Change Healthcare's advantage is its scale and depth of payer data, given UnitedHealth's dual role as payer and technology vendor. However, provider organizations may hesitate to adopt a tool owned by the largest US health insurer due to competitive concerns and data-sharing apprehensions. Cohere offers a more neutral third-party posture, though it lacks the network effects and data breadth that come with UnitedHealth's footprint.

Surescripts operates an electronic prior authorization network that connects EHRs, pharmacies, and payers for medication-specific PA requests. Surescripts excels in pharmacy-based workflows but does not extend to procedure authorizations, imaging approvals, or durable medical equipment. Cohere addresses a broader scope of PA use cases, making it complementary rather than directly competitive to Surescripts. Organizations already using Surescripts for medication PA should evaluate whether Cohere's procedural automation justifies adding a second vendor to the stack.

Olive AI, which shut down in 2023 after raising over $850 million, serves as a cautionary tale for AI-driven healthcare automation platforms. Olive promised broad administrative automation including prior authorization, but failed to deliver validated ROI at scale. Cohere's enterprise model and narrower focus on PA reduce some of the risks that plagued Olive, but the absence of published validation studies and the reliance on vendor-reported automation rates echo the same credibility gaps that undermined confidence in Olive. Prospective buyers should demand contractual performance guarantees and independent audit rights to avoid a similar outcome.

What clinicians say

Cohere Health has generated zero mentions in the r/medicine, r/Residency, or r/HealthIT Reddit communities as of this review, indicating the platform has not yet penetrated grassroots clinical conversations. This absence is common for payer-side enterprise tools that do not directly interface with front-line clinicians, but it limits the availability of candid user feedback outside vendor-managed reference calls. Prospective buyers should interpret the lack of organic clinician discussion as a data gap rather than a negative signal, but should not rely on anecdotal endorsements from sales materials as a substitute for independent validation.

The broader prior authorization discussion among clinicians on social media and professional forums centers on administrative burden, arbitrary denials, and the perception that PA workflows prioritize cost control over patient care. Physicians frequently cite prior authorization as a leading contributor to burnout, with particular frustration directed at requests for evidence-based treatments that are later approved after time-consuming appeals. If Cohere's automation accelerates approval for clinically appropriate requests while maintaining or increasing denial rates for edge cases, it may reduce administrative time without addressing the underlying physician dissatisfaction with PA as a utilization management tool.

In the absence of direct clinician feedback on Cohere, prospective buyers should assess whether the platform's workflows align with the pain points most commonly cited in PA-related clinician surveys. Key usability questions include whether the system provides real-time denial rationales, whether it allows clinicians to escalate to peer-to-peer review without navigating separate payer portals, and whether it reduces redundant documentation requests when clinical notes already contain the necessary justification. Organizations should pilot the platform with a representative sample of specialties and gather structured clinician feedback before committing to full-scale deployment.

What the literature says

Cohere Health has zero indexed citations in PubMed as of this review, meaning the platform's clinical impact, accuracy, and automation performance have not been validated in peer-reviewed journals. The absence of published research is common for early-stage healthcare IT vendors and enterprise tools that serve payers rather than direct clinical workflows, but it represents a significant evidence gap for organizations seeking to justify adoption based on proven outcomes. Prospective buyers should require the vendor to share de-identified performance data from existing deployments, ideally audited by a third party, to assess whether the 90 percent automation claim holds across diverse clinical contexts.

The broader literature on prior authorization automation and AI-driven utilization management is sparse, with most published studies focusing on manual PA burden rather than automated solutions. A 2022 survey published in Health Affairs found that prior authorization requirements delayed care for 94 percent of physicians and led to treatment abandonment for 32 percent of patients, underscoring the clinical urgency of reducing PA friction. However, studies evaluating whether AI-based automation preserves clinical appropriateness while reducing administrative time are largely absent from the evidence base, leaving vendors like Cohere to rely on case studies and customer testimonials rather than controlled trials.

The lack of peer-reviewed validation for Cohere Health and similar PA automation platforms raises questions about transparency, accountability, and the risk of algorithmic bias. If the platform's rules engines systematically deny requests for certain specialties, patient populations, or treatment modalities, those patterns may not surface until after widespread deployment. Organizations should negotiate contract terms that include regular audits of approval and denial rates stratified by demographic and clinical variables, with independent third-party review to detect unintended bias. Until published research validates the safety and efficacy of AI-driven PA automation, early adopters bear the responsibility of generating that evidence through rigorous internal evaluation.

Who it's for

Cohere Health is best suited for integrated delivery networks, large medical groups, and accountable care organizations operating under value-based contracts with significant prior authorization volumes. These organizations have the IT resources to manage EHR integration, the procurement leverage to negotiate enterprise contracts, and the strategic alignment with payers to benefit from Cohere's payment integrity and care management positioning. Chief medical information officers, revenue cycle directors, and care transformation leaders responsible for reducing administrative burden while maintaining clinical appropriateness will find the platform's dual-sided workflow most relevant.

Payer organizations seeking to modernize utilization management and reduce medical director review queues are the platform's primary buyer persona. Health plans with provider networks that generate high PA volumes across multiple specialties can deploy Cohere to automate routine approvals, freeing medical directors to focus on complex cases requiring clinical judgment. Payers balancing cost control objectives with provider satisfaction metrics will appreciate the platform's transparency features and real-time status tracking, which reduce friction even when denials occur.

Solo practitioners, small group practices, community health centers, and rural hospitals should skip Cohere Health due to the enterprise-only business model and the coordination overhead required for deployment. These organizations will find better value in provider-side PA automation tools like CoverMyMeds, Surescripts, or EHR-embedded workflows that do not require payer participation. Specialty practices with narrow service lines should also assess whether Cohere's automation rates hold for their specific procedure mix before committing, as vendor claims may reflect performance in high-volume primary care settings rather than niche specialties.

The verdict

Cohere Health represents a credible attempt to address prior authorization friction through payer-provider collaboration and AI-driven automation, but the platform's value proposition depends on claims that remain unvalidated by independent research or grassroots clinician feedback. The 90 percent automation rate, if achievable across diverse clinical contexts, would materially reduce administrative burden for both providers and payers. However, the absence of published data, the lack of transparent pricing, and the enterprise-only distribution model limit accessibility and accountability. Organizations with the resources to pilot Cohere and the leverage to negotiate performance guarantees should consider it, but only with contractual protections and rigorous internal evaluation.

For large health systems and payers aligned on value-based care goals, Cohere is worth a structured pilot in a defined service line or specialty. Success criteria should include measurable reductions in PA turnaround time, sustained or improved approval rates for clinically appropriate requests, and clinician feedback confirming that automation reduces rather than redistributes administrative work. If the pilot meets those thresholds, broader deployment may deliver ROI. If automation rates fall short or if the platform introduces new documentation friction, organizations should retain the contractual right to terminate without penalty.

Small practices, safety-net providers, and specialty groups should wait for independent validation and broader market adoption before considering Cohere. The evidence gap is too large, and the barriers to entry too high, for organizations without dedicated IT and procurement teams. Until peer-reviewed studies confirm the platform's efficacy and until grassroots clinician communities report positive experiences, Cohere remains a plausible but unproven solution best suited for early-adopter health systems willing to serve as their own validators.